



Republic of the Philippines
DEPARTMENT OF HEALTH
OFFICE OF THE SECRETARY
PURCHASE ORDER

Procurement of Tamoxifen 20mg Tablet

IB No. 2018-076

Supplier: **Pharmastar Int'l Trading Corp.**

PO No.: **GOP-2018-07-159**

Address: #8 Felipe Pike St., Green Valley Subdivision, Brgy. Pangasinan-Ilog, Pasig City

Date: **AUG 09 2018**

Telephone No. Tel No. (02) 501-4865 / 501-4693 Fax No. (02) 661-7933

Competitive Bidding

TIN 007-162-170-000

Sir/Madam:

Mode of Procurement:

Please furnish this office of the following articles subject to the terms and conditions contained herein:

Place of Delivery: Please refer to "Annex A" for the Allocation List

Delivery Term:

Date of Delivery: Sixty (60) calendar days upon receipt of approved Notice to Proceed

Mode of Payment:

Upon Delivery and Acceptance

Item No.	Unit	Description	Quantity	Unit Cost	Amount
1	tablet	Tamoxifen Name of Manufacturer: Celogen Pharma Pvt., Ltd. Country of Origin: India Brand: Tamoxigen 20 Technical Specification: <ul style="list-style-type: none">• 20mg tablet• Must be commercially available in the Philippine market for the past two (2) years Upon delivery the following shall be complied with: <ul style="list-style-type: none">• Shelf Life: Shelf life of at least <i>twenty four (24) months</i> from the date of manufacture but not less than <i>eighteen (18) months</i> from the date of delivery.• Packaging Instructions: Standard packaging of the manufacturer including package insert or encryption/imprint inside the box as approved by Philippine Food and Drug Administration (PFDA).• Labeling Instructions: Standard labeling instruction as approved by PFDA pursuant to Administrative Order No. 2016-0008. In addition to the labeling requirement of FDA: <ul style="list-style-type: none">• On each blister pack/foil strip/bottle and box the following should be legibly imprinted or stickered with non-removable or permanent sticker/label that is binding and with residue and tearing, if removed: <div style="text-align: center;">Philippine Government Property-DOH / Department of Health Not for Sale</div>• On each corrugated carton, the following should be legibly imprinted or stickered with non-removable or permanent sticker/label that is binding and with residue and tearing, if removed: <div style="text-align: center;">Philippine Government Property-DOH / Department of Health Not for Sale</div><div style="text-align: center;">Manufacturing Date: _____ Expiration Date: _____ Batch/Lot No.: _____</div>• Product Recall/Replacement The supplier must ensure the quality of drugs and if there will be problems in the quality, the supplier will recall and replace the drugs distributed in the regions and health centers based on the Guidelines on Product Recall, FDA Circular No. 2016-012. The inspection and tests that will be conducted are: <ol style="list-style-type: none">1. Upon delivery, the Goods shall undergo preliminary physical inspection by the Inspection Team of the PROCURING ENTITY to ascertain the physical condition and acceptability of the Goods.2. The supplier shall promptly replace the equivalent quantity of Goods taken as samples without cost to the PROCURING ENTITY.	850,100	3.50	2,975,350.00
Purpose: Procurement for Breast Cancer Sub-Program Note: Subject to the conditions stated in the Bidding Documents					

Two Million Nine Hundred Seventy Five Thousand Three Hundred Fifty Philippine Pesos

2,975,350.00

Liquidated Damages (Section 68 of the Revised IRR of RA9184): All contracts executed in accordance with the Act and this IRR shall contain a provision on liquidated damages which shall be payable by the contractor in case of breach thereof. For the procurement of Goods, Infrastructure Projects and Consulting Services, the amount of liquidated damages shall be at least equal to one-tenth of one percent (0.001) of the cost of the unperformed portion for every day of delay. Once the cumulative amount of liquidated damages reaches ten percent (10%) of the amount of the contract, the Procuring Entity may rescind or terminate the contract, without prejudice to other courses of action and remedies available under the circumstances.

Warranty (Section 62 of the Revised IRR of RA 9184): In order to assure that manufacturing defects shall be corrected by the supplier, a warranty security shall be required from the contract awardee for a minimum period of three (3) months, in the case of Expendable Supplies, or a minimum period of one (1) year, in the case of Non-expendable Supplies, after acceptance by the Procuring Entity of the delivered supplies. The obligation for warranty shall be covered by either retention money in an amount equivalent to at least one percent (1%) but not to exceed five percent (5%) of every progress payment, or a special bank guarantee equivalent to at least one percent (1%) but shall not exceed five percent (5%) of the total contract price. The said amounts shall only be released after the lapse of the warranty period, or, in the case of Expendable Supplies, after consumption thereof. Provided, however, that the supplies delivered are free from patent and latent defects and all the conditions imposed under the contract have been fully met.



Republic of the Philippines
DEPARTMENT OF HEALTH
OFFICE OF THE SECRETARY
PURCHASE ORDER

Procurement of Tamoxifen 20mg Tablet

13 No. 2018-076

Supplier:	Pharmastar Int'l Trading Corp.	PO No.:	GOP-2018-07-159
Address:	#8 Felipe Pike St., Green Valley Subdivision, Brgy. 3seping-llog, Pasig City	Date:	
Telephone No.	Tel No. (02) 501-4865 / 501-4693 Fax No. (02) 661-7933	Mode of Procurement:	AUG 08 2018 Competitive Bidding
TIN	007-162-170-000		
Sir/Madam:			
Please furnish this office of the following articles subject to the terms and conditions contained herein:			
Place of Delivery:	Please refer to "Annex A" for the Allocation List	Delivery Term:	
Date of Delivery:	Sixty (60) calendar days upon receipt of approved Notice to Proceed	Mode of Payment:	Upon Delivery and Acceptance
Conforme:		By Authority of the Secretary of Health:	
Signature Over Printed Name of Supplier <i>Orlando B. Mendoza</i> Date <i>SEP 11 18</i>		<i>Mecary</i> MYRNA C. CABOTALE, MD, MPH, CESO III Director IV Disease Prevention and Control Bureau ORS/BUURS No.: <i>02-104401-2018-08-00070</i> Date of the ORS/BUURS: <i>8-7-18</i> Amount: <i>P2,9K 350.00</i>	
Fund Cluster:			
Funds Available:	<i>SEP 9 18</i> LORICA C. RABAGO OIC ACCOUNTING DIVISION		
San Lazaro Compound, Rizal Avenue, 3rd, Crd., 1003 Manila • Trunk Line 651-7800 local 1108, 1111, 1112, 1113 Direct Line: 711-9502; 711-9503 Fax: 761-7939 • URL: http://www.doh.gov.ph ; e-mail: info@doh.gov.ph			

PS / COBAC

APPROVED PO / CONTRACT

Received by: *[Signature]*

Date: *SEP 20 2018*

PS / COBAC

RELEASED: PO / CONTRACT

by: *[Signature]*

Date: *SEP 01 2018*